Table 4 LSM differences in change from baseline in the EQ-5D HSI and EQ-5D VAS scores between (A) panitumumab + FOLFOX4 vs FOLFOX4 alonea (B) panitumumab + FOLFIRI vs FOLFIRI aloneb, using pattern mixture models

From: Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment

(A)

      
 

EQ-5D HIS

EQ-5D VAS

Dropout group

Panitumumb + FOLFOX4 ( n =279)

FOLFOX4 ( n =289)

Difference

Panitumumb + FOLFOX4 ( n =278)

FOLFOX4 ( n =285)

Difference

Late/completer

0.058

0.062

−0.004

4.008

4.392

−0.384

(95% CI)

(0.032, 0.084)

(0.033, 0.091)

(−0.043, 0.035)

(1.677, 6.339)

(1.887, 6.898)

(−3.799, 3.030)

Early

−0.006

0.014

−0.020

−0.873

0.795

−1.668

(95% CI)

(−0.030, −0.018)

(−0.008, 0.036)

(−0.053, 0.012)

(−2.872, 1.125)

(−1.057, 2.646)

(−4.390, 1.054)

(B)

      
 

EQ-5D HIS

EQ-5D VAS

Dropout group

Panitumumb + FOLFIRI ( n =262)

FOLFIRI ( n =265)

Difference

Panitumumb + FOLFIRI ( n =257)

FOLFIRI ( n =259)

Difference

Late/completer

0.023

0.025

−0.002

1.575

3.310

−1.735

(95% CI)

(−0.008, 0.053)

(−0.011, 0.060)

(−0.048, 0.044)

(−0.477, 3.627)

(0.875, 5.745)

(−4.913, 1.443)

Early

−0.059

−0.008

−0.051

−3.675

−1.866

−1.809

(95% CI)

(−0.084, −0.034)

(−0.031, 0.015)

(−0.085, −0.017)

(−5.349, −2.002)

(−3.406, −0.326)

(−4.090, 0.471)

  1. Abbreviations: CI=confidence interval; EQ-5D=EuroQoL-5 dimensions; FOLFIRI=fluorouracil, leucovorin and irinotecan; FOLFOX=fluorouracil, leucovorin and oxaliplatin; HSI=Health State Index; LSM=least squares mean; VAS=Visual Analogue Scale.
  2. Early drop out is defined as study dropout on or before aweek 28 in the first-line trial; bweek 20 in the second-line trial.
Back to article page